Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, headquartered in Frederick, Maryland. The company is advancing a pipeline of cell therapy candidates targeting serious autoimmune conditions. Cartesian is publicly traded on the Nasdaq exchange.

Cell programming and synthetic biology platform. Boston MA. General Atlantic + Cascade. IPO 2021. NYSE: DNA. MIT spinout.

Violet Therapeutics is a preclinical-stage biotechnology company headquartered in Somerville, Massachusetts, developing first-in-class therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's by targeting EphB3 inhibitors to reduce neuroinflammation. The company raised a $4.75M seed extension in May 2026 to advance its novel therapeutic for synaptic preservation and repair.